Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133367 · ClinicalTrials.gov registry record · Phase 2
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
A Phase 2 study of Multiple Myeloma and Non-Hodgkin's Lymphoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT00133367 is a Phase 2 study of Multiple Myeloma and Non-Hodgkin's Lymphoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00133367, a Phase 2 study of Multiple Myeloma and Non-Hodgkin's Lymphoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to measure the effectiveness of 2 drugs, tacrolimus and sirolimus, in preventing graft versus host disease (GVHD) after treatment with chemotherapy followed by donor cord blood transplantation.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG G-CSF
- DRUG Thymoglobulin
- DRUG Tacrolimus
- DRUG Antithymocyte globulin
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133367
The ClinicalTrials.gov registry entry for NCT00133367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Sirolimus is the first listed.
NCT00133367 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00133367 about?
NCT00133367 is a clinical study titled "Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus". The purpose of this study is to measure the effectiveness of 2 drugs, tacrolimus and sirolimus, in preventing graft versus host disease (GVHD) after treatment with chemotherapy followed by donor cord blood transplantation.
What is the current status of trial NCT00133367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2005-08. Estimated completion is 2011-11.
What conditions does trial NCT00133367 study?
This clinical trial studies the following conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Lymphoblastic Leukemia, Myelogenous Leukemia.
What interventions are being tested in trial NCT00133367?
The interventions under investigation include: Sirolimus (DRUG), G-CSF (DRUG), Thymoglobulin (DRUG), Tacrolimus (DRUG), Antithymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00133367?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00133367 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.